Back
47· Steady
Markets3h 59m ago
Enlivex announced the issuance of an Australian patent covering the use of Allocetra™ for treating osteoarthritis, providing intellectual property protection in Australia through at least 2040.
Archive Window: 7 Days Left
Nes-Ziona, Israel; Australia
Who
Enlivex Ltd.
What
Enlivex announced the issuance of an Australian patent covering the use of Allocetra™ for treating osteoarthritis, providing intellectual property protection in Australia through at least 2040.
When
Mon, 15 Jun 2026 12:09:38 GMT · 3h 59m ago
Where
Nes-Ziona, Israel; Australia ·
Why
This patent issuance strengthens Enlivex's global intellectual property position as its Phase 2b clinical program for Allocetra™ advances.
The Frontline Impact
How this affects you
Enlivex, a biotechnology company, has secured patent protection for its Allocetra™ treatment in Australia, signifying progress in its clinical trials and potentially increasing its market value and intellectual property portfolio in the biopharmaceutical sector.
Story chain
2 events in this thread- Markets3h 59m agoEnlivex Ltd. announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS,” which provides intellectual property protection in Australia through at least 2040.Open article
- Currently Reading3h 59m agoEnlivex announced the issuance of an Australian patent covering the use of Allocetra™ for treating osteoarthritis, providing intellectual property protection in Australia through at least 2040.